Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDO
Active, not recruitingNCT05033756
Institut fuer FrauengesundheitBreast Cancer, Malignant Neoplasm of Breast
Start: 2022-07-30End: 2026-02-28Updated: 2024-05-07